Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ARDX, ITRM and ATIP By: The Klein Law Firm via AccessWire September 10, 2021 at 17:45 PM EDT NEW YORK, NY / ACCESSWIRE / September 10, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.Ardelyx, Inc. (NASDAQ:ARDX)Class Period: August 6, 2020 - July 19, 2021Lead Plaintiff Deadline: September 28, 2021The ARDX lawsuit alleges that throughout the class period, Ardelyx, Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.Learn about your recoverable losses in ARDX: https://www.kleinstocklaw.com/pslra-1/ardelyx-inc-loss-submission-form?id=19498&from=1Iterum Therapeutics Plc (NASDAQ:ITRM)Class Period: November 30, 2020 - July 23, 2021Lead Plaintiff Deadline: October 4, 2021Iterum Therapeutics Plc allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Learn about your recoverable losses in ITRM: https://www.kleinstocklaw.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?id=19498&from=1ATI Physical Therapy, Inc. f/k/a Fortress Value Acquisition Corp. II (NYSE:ATIP)This lawsuit is on behalf of investors who: (a) purchased or otherwise acquired ATI securities between April 1, 2021 and July 23, 2021, inclusive and/or (b) held FVAC Class A common stock as of May 24, 2021 and were eligible to vote at FVAC's June 15, 2021 special meeting.Lead Plaintiff Deadline: October 15, 2021The complaint alleges that during the class period ATI Physical Therapy, Inc. f/k/a Fortress Value Acquisition Corp. II made materially false and/or misleading statements and/or failed to disclose that: (1) ATI was experiencing attrition among its physical therapists; (2) ATI faced increasing competition for clinicians in the labor market; (3) as a result of the foregoing, the Company faced difficulties retaining therapists and incurred increased labor costs; (4) as a result of the labor shortage, the Company would open fewer new clinics; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.Learn about your recoverable losses in ATIP: https://www.kleinstocklaw.com/pslra-1/ati-physical-therapy-inc-f-k-a-fortress-value-acquisition-corp-ii-loss-submission-form?id=19498&from=1Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:J. Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY 10118jk@kleinstocklaw.comTelephone: (212) 616-4899Fax: (347) 558-9665www.kleinstocklaw.comSOURCE: The Klein Law FirmView source version on accesswire.com: https://www.accesswire.com/663624/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-ARDX-ITRM-and-ATIP Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ARDX, ITRM and ATIP By: The Klein Law Firm via AccessWire September 10, 2021 at 17:45 PM EDT NEW YORK, NY / ACCESSWIRE / September 10, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.Ardelyx, Inc. (NASDAQ:ARDX)Class Period: August 6, 2020 - July 19, 2021Lead Plaintiff Deadline: September 28, 2021The ARDX lawsuit alleges that throughout the class period, Ardelyx, Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.Learn about your recoverable losses in ARDX: https://www.kleinstocklaw.com/pslra-1/ardelyx-inc-loss-submission-form?id=19498&from=1Iterum Therapeutics Plc (NASDAQ:ITRM)Class Period: November 30, 2020 - July 23, 2021Lead Plaintiff Deadline: October 4, 2021Iterum Therapeutics Plc allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Learn about your recoverable losses in ITRM: https://www.kleinstocklaw.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?id=19498&from=1ATI Physical Therapy, Inc. f/k/a Fortress Value Acquisition Corp. II (NYSE:ATIP)This lawsuit is on behalf of investors who: (a) purchased or otherwise acquired ATI securities between April 1, 2021 and July 23, 2021, inclusive and/or (b) held FVAC Class A common stock as of May 24, 2021 and were eligible to vote at FVAC's June 15, 2021 special meeting.Lead Plaintiff Deadline: October 15, 2021The complaint alleges that during the class period ATI Physical Therapy, Inc. f/k/a Fortress Value Acquisition Corp. II made materially false and/or misleading statements and/or failed to disclose that: (1) ATI was experiencing attrition among its physical therapists; (2) ATI faced increasing competition for clinicians in the labor market; (3) as a result of the foregoing, the Company faced difficulties retaining therapists and incurred increased labor costs; (4) as a result of the labor shortage, the Company would open fewer new clinics; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.Learn about your recoverable losses in ATIP: https://www.kleinstocklaw.com/pslra-1/ati-physical-therapy-inc-f-k-a-fortress-value-acquisition-corp-ii-loss-submission-form?id=19498&from=1Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:J. Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY 10118jk@kleinstocklaw.comTelephone: (212) 616-4899Fax: (347) 558-9665www.kleinstocklaw.comSOURCE: The Klein Law FirmView source version on accesswire.com: https://www.accesswire.com/663624/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-ARDX-ITRM-and-ATIP